Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics (Q81600958)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

Ana Maria Gonzalez-Angulo

10 January 2020

author

series ordinal

2

object named as

Ana Maria Gonzalez-Angulo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1

Bryan T Hennessy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Gabriel N Hortobagyi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

598-599

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0375

7 January 2021

Identifiers

DOI

10.1038/NCPONC0375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341096%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference